[New Drug Spotlight] Aficamten - a next-in-class oral cardiac myosin inhibitor for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM)

Aficamten (brand name Myqorzo) is a next-in-class, oral cardiac myosin inhibitor originally discovered and developed by Cytokinetics.

[New Drug Spotlight] Pimicotinib - a potential “Best-in-Class” oral, selective CSF-1R inhibitor for tenosynovial giant cell tumor (TGCT)

Pimicotinib is an oral small-molecule, highly selective CSF-1R inhibitor developed by Abbisko Therapeutics.

[Commercial Synthesis Spotlight] Process Development of (S)-2-Methylproline for Daridorexant

α-Substituted proline derivatives are widely used in medicinal chemistry, particularly in peptide-based drug discovery and peptidomimetic design.

[New Drug Spotlight] Ceralasertib - an oral ATR inhibitor disrupting DNA damage checkpoint signaling to enhance tumor sensitivity to replication stress and DNA-damaging therapies

Ceralasertib is an oral ATR (ataxia-telangiectasia and Rad3-related) kinase inhibitor developed by AstraZeneca and currently being evaluated in late-stage clinical trials for advanced solid tumors (for example, post-immunotherapy or platinum-treated NSCLC and ovarian cancer).

[New Drug Spotlight] Imlunestrant - A next-generation oral selective estrogen receptor degrader (SERD) targeting endocrine-resistant and ER-mutant breast cancer

Imlunestrant (brand name Inluriyo®) is an oral small-molecule selective estrogen receptor degrader (SERD) developed by Eli Lilly.

[Commercial Synthesis Spotlight] Process Route Development of a Key Pyrazine Building Block

Nitrogen-containing heterocycles play a pivotal role in modern medicinal chemistry, particularly pyrazine structures, which are widely applied in oncology research and other therapeutic areas.

[New Drug Spotlight] Remibrutinib - A first-in-class oral BTK inhibitor targeting mast-cell and B-cell–mediated inflammation in CSU

Remibrutinib (trade name Rhapsido®) was approved by the U.S. FDA on September 30, 2025, for the treatment of adults with chronic spontaneous urticaria (CSU) who have an inadequate response to H1 antihistamines.

[New Drug Spotlight] Seralutinib - A Next-Generation Inhaled Tyrosine Kinase Inhibitor Targeting Pulmonary Vascular Remodeling in PAH

Seralutinib is a next-generation inhaled small-molecule tyrosine kinase inhibitor developed by Gossamer Bio and is currently in Phase 3 clinical trials for the treatment of pulmonary arterial hypertension (PAH).